Systematic Review of Episodic Migraine Prophylaxis: Efficacy of Conventional Treatments Used in Comparisons with Acupuncture
Abstract
Objective: A Cochrane Systematic Review published by Linde et al. in 2016 found moderate evidence suggesting that acupuncture is “at least non-inferior” to conventional prophylactic drug treatments (flunarizine, metoprolol, and valproic acid) for episodic migraine prophylaxis. The evidence for the efficacy of these conventional treatments must be verified to strengthen and validate the original comparison made in Linde et al.'s 2016 review. The aim of the current authors' systematic review was to verify the efficacy of the conventional treatments used in Linde et al.'s 2016 comparison with acupuncture.
Materials and Methods: Search strategies were applied to find studies that could verify the efficacy of conventional treatments for treating episodic migraines. Relevant outcomes and dosages were extracted from the retrieved studies. Each study's quality was assessed, using the Cochrane's collaboration tool for assessing risk of bias and the Cochrane GRADE [Grading of Recommendations Assessment, Development, and Evaluation] scale.
Results: There is high-quality evidence suggesting that prophylactic drug treatment, at the treatment dosage ranges used in Linde et al.'s 2016 review, reduced headache frequency at a 3-month follow-up, compared to placebo. Headache frequency at a 6-month follow-up, and responses (at least 50% reduction of headache frequency) at 3-month and 6-month follow-ups could not be assessed.
Conclusions: These findings strengthened Linde et al.'s 2016 comparison of conventional treatments and acupuncture for reducing headache frequency at a 3-month follow-up. For episodic migraine prophylaxis, moderate evidence suggests that acupuncture is “at least non-inferior,” to now-proven, conventional treatments. This raises significant questions in the debate concerning claims that acupuncture is a placebo-based treatment and the prescriptions of proven conventional treatments that have similar effects as acupuncture.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Astin JA. Why patients use alternative medicine: Results of a national study. JAMA. 1998;279(19):1548–1553.
2. Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev. 2016;6:CD001218.
3. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: Updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.
4. Moffet HH. Sham acupuncture may be as efficacious as true acupuncture: A systematic review of clinical trials. J Altern Complement Med. 2009;15(3):213–216.
5. Vickers AJ, Vertosick EA, MacPherson H, et al.; Acupuncture Trialists' Collaboration. Acupuncture for chronic pain: Update of an individual patient data meta-analysis. J Pain. 2018;19(5):455–474.
6. Hesse J, Møgelvang B, Simonsen H. Acupuncture versus metoprolol in migraine prophylaxis: A randomized trial of trigger point inactivation. J Intern Med. 1994;235(5):451–456.
7. Streng A, Linde K, Hoppe A, et al. Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis. Headache. 2006;46(10):1492–1502.
8. Diener HC, Kronfeld K, Boewing G, et al.; GERAC Migraine Study Group. Efficacy of acupuncture for the prophylaxis of migraine: A multicentre randomised controlled clinical trial. Lancet Neurol. 2006;5(4):310–316.
9. Allais G, De Lorenzo C, Quirico PE, Airola G, Tolardo G, Mana O, Benedetto C. Acupuncture in the prophylactic treatment of migraine without aura: A comparison with flunarizine. Headache. 2002;42(9):855–861.
10. Facco E, Liquori A, Petti F, Fauci AJ, Cavallin F, Zanette G. Acupuncture versus valproic acid in the prophylaxis of migraine without aura: A prospective controlled study. Minerva Anestesiol. 2013;79(6):634–642.
11. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009;1:CD001218.
12. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
13. Higgins JP, Altman DG, Gøtzsche PC, et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
14. Guyatt G, Oxman AD, Akl EA., et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
15. Frenken CW, Nuijten ST. Flunarizine, a new preventive approach to migraine: A double-blind comparison with placebo. Clin Neurol Neurosurg. 1984;86(1):17–20.
16. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache. 1981;21(6):235–239.
17. Mendenopoulos G, Manafi T, Logothetis I, Bostantjopoulou S. Flunarizine in the prevention of classical migraine: A placebo-controlled evaluation. Cephalalgia. 1985;5(1):31–37.
18. Sørensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6(1):7–14.
19. Sorge F, De Simone R, Marano E, Nolano M, Orefice G, Carrieri P. Flunarizine in prophylaxis of childhood migraine: A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988;8(1):1–6.
20. Lepcha A, Amalanathan S, Augustine A, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: A randomized controlled trial. Eur Arch Otorhinolaryngol. 2013;271(11):2931–2936.
21. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN, de Fine Olivarius B. Prophylactic treatment of classical and non-classical migraine with metoprolol—a comparison with placebo. Cephalalgia. 1983;3(4):207–212.
22. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: Parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28(1):15–23.
23. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611.
24. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia. 1992;12(2):81–84.
25. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology. 1994;44(4):647–651.
26. Porter RS, Kaplan JL; Merck & Co. Merck Manual of Diagnosis and Therapy, 19th ed. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2011.
27. Zheng YC, Yuan TT, Liu T. Is acupuncture a placebo therapy? Complement Ther Med. 2014;22(4):724–730.
Information & Authors
Information
Published In

Medical Acupuncture
Volume 31 • Issue Number 2 • April 2019
Pages: 85 - 97
Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers.
History
Published online: 19 April 2019
Published ahead of print: 4 April 2019
Published in print: April 2019
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.